Paul O'Meara is returning to Ipsos Healthcare as Head of Autoimmune Therapy Monitors, based in NYC. He replaces Sabina Heinz who moves to head up the company's Diabetes, Cardiovascular and Respiratory portfolios, along with a number of new monitors.
O'Meara spent seven years at Synovate and then Ipsos Healthcare before leaving in 2012 to join Insight Health US as Head of Syndicated Services. In his previous spell with Synovate / Ipsos he worked in London, setting up the Global Psoriasis and Global IBD Therapy Monitors, then relocated to New York to promote the Autoimmune Therapy Monitors, and then to Shanghai to head up Ipsos Healthcare's Syndicated Services in Asia Pacific. He began at pharmaceutical company Schering-Plough.
A regular contributor to scientific research with papers on bioinformatics and computational genetics, O'Meara holds an MSc in computational genetics from Imperial College London.
Rhoda Schmuecking, the firm's President of Global Therapy Monitors, comments: 'These Global Therapy Monitor portfolios are core elements of our syndicated offering, and I'm delighted that we have such strong leaders in place for both teams.' O'Meara says autoimmune disorders represent 'a dynamic and prominent growth segment of the pharmaceutical industry'.
Web site: www.ipsos.com .
All articles 2006-20 written and edited by Mel Crowther and/or Nick Thomas unless otherwise stated.